SCHEMBL324691

SCHEMBL324691

CC(C)(C)OC(=O)N1CCNCC1(C)C

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
USP2 O75604 1/20 0.38
SMN1; SMN2 Q16637 1/20 0.38
CTSK P43235 1/20 0.37
MAPK1 P28482 1/20 0.34
NR1H2 P55055 1/20 0.33
EPHX2 P34913 1/20 0.33
HPGD P15428 1/20 0.33
CHRM2 P08172 1/20 0.33
CHRM1 P11229 1/20 0.33
CHRM3 P20309 1/20 0.33
MEN1 O00255 1/20 0.32
KMT2A Q03164 1/20 0.32
GRIN2B Q13224 1/20 0.32
GRIN2C Q14957 1/20 0.32
DDB1 Q16531 1/20 0.32
CRBN Q96SW2 1/20 0.32
MAPT P10636 2/20 0.31
BUB1 O43683 1/20 0.31
KDM4E B2RXH2 1/20 0.31
THRB P10828 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL18096129 0.98 USP2 (0.37) USP2SMN1; SMN2CTSKMAPK1NR1H2
Methane SCHEMBL29102488 0.93 CTSK (0.33) USP2SMN1; SMN2CTSKMAPK1
SCHEMBL27121465 0.90 CTSK (0.39) USP2SMN1; SMN2CTSKMAPK1NR1H2
SCHEMBL25694549 0.85 USP2 (0.37) USP2SMN1; SMN2CTSKMAPK1NR1H2
SCHEMBL25847564 0.84 USP2 (0.36) USP2SMN1; SMN2CTSKMAPK1NR1H2
SCHEMBL28724815 0.83 USP2 (0.38) USP2SMN1; SMN2CTSKMAPK1NR1H2
SCHEMBL5478401 0.83 USP2 (0.35) USP2SMN1; SMN2CTSKMAPK1NR1H2
SCHEMBL16636874 0.83 USP2 (0.35) USP2SMN1; SMN2CTSKMAPK1NR1H2
SCHEMBL28670928 0.83 USP2 (0.35) USP2SMN1; SMN2CTSKMAPK1NR1H2
SCHEMBL38663950 0.82 USP2 (0.37) USP2SMN1; SMN2CTSKMAPK1NR1H2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 465 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-114245753-A Combination of an anti-HER 2 antibody and a CDK inhibitor for tumor therapy 江苏康宁杰瑞生物制药有限公司 2022-03-25 CN claimed
CN-215962198-U N-Boc-2, 2 dimethylpiperazine's rectifier unit 白银乐天园化学有限责任公司 2022-03-08 CN claimed
US-12637458-B2 Imidazo[1,2-a]pyridine compounds and their use in therapy IMPERIAL COLLEGE INNOVATIONS LIMITED (GB) 2026-05-26 US disclosed
WO-2026106389-A1 NMT INHIBITOR AND USE THEREOF 주식회사 이노보테라퓨틱스 2026-05-21 WO disclosed
US-20260109716-A1 CEREBLON-BASED KRAS DEGRADING PROTACS AND USES RELATED THERETO ARVINAS OPERATIONS, INC. (US) 2026-04-23 US disclosed
EP-4727932-A1 SMALL MOLECULE LIGANDS AND APTAMERS MeiraGTx Gene Regulation Limited (GB) 2026-04-22 EP disclosed
EP-4709725-A1 HETEROCYCLIC COMPOUNDS AND USES THEREOF Progentos Therapeutics, Inc. (US) 2026-03-18 EP disclosed
EP-4711369-A1 1H-[1,2,3]TRIAZOLO[4,5-H]QUINAZOLINE COMPOUNDS AS PROTEIN KINASE INHIBITORS Chengdu Cynogen Bio-Pharmaceutical Technology Co., Ltd. (CN) 2026-03-18 EP disclosed
EP-4704830-A2 MRGPRX2 INHIBITORS AND METHODS OF USE THEREOF Septerna, Inc. (US) 2026-03-11 EP disclosed
US-20260062426-A1 CYCLIN DEPENDENT KINASE DEGRADERS AND METHODS OF USE THEREOF DIFFERENTIATED THERAPEUTICS INC (US) 2026-03-05 US disclosed
EP-4694889-A1 COMPOUNDS AND METHODS FOR TREATING PROTEIN AGGREGATION DISEASES Acelot, Inc. (US) 2026-02-18 EP disclosed
WO-2007127175-A2 PHARMACEUTICAL COMPOUNDS F. HOFFMANN-LA ROCHE AG (CH) 2007-11-08 WO disclosed
US-20070232617-A1 INDOLE-TYPE DERIVATIVES AS INHIBITORS OF P38 KINASE SCIOS, INC. (US) 2007-10-04 US disclosed
EP-1805158-A1 SULFONYL-SUBSTITUTED BICYCLIC COMPOUNDS AS MODULATORS OF PPAR Kalypsys, Inc. (US) 2007-07-11 EP disclosed
US-7220763-B2 Indole-type derivatives as inhibitors of p38 kinase SCIOS, INC. (US) 2007-05-22 US disclosed
EP-1545528-A4 INDOLE-TYPE DERIVATIVES AS INHIBITORS OF P38 KINASE SCIOS INC (US) 2006-07-26 EP disclosed
WO-2006055187-A1 SULFONYL-SUBSTITUTED BICYCLIC COMPOUNDS AS MODULATORS OF PPAR KALYPSYS, INC. (US) 2006-05-26 WO disclosed
EP-1545528-A2 INDOLE-TYPE DERIVATIVES AS INHIBITORS OF P38 KINASE SCIOS INC. (US) 2005-06-29 EP disclosed
US-20040142940-A1 Indole-type derivatives as inhibitors of p38 kinase SCIOS, INC. 2004-07-22 US disclosed
WO-2004022712-A2 INDOLE-TYPE DERIVATIVES AS INHIBITORS OF p38 KINASE SCIOS INC. (US) 2004-03-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040142940-A1 Indole-type derivatives as inhibitors of p38 kinase MAPK1, MAPKAPK2, MAPK4 USP2 2623/4885SMN1; SMN2 3757/4885CTSK 3503/4885
US-20260062426-A1 CYCLIN DEPENDENT KINASE DEGRADERS AND METHODS OF USE THEREOF CCNA1, CCNE1, CCNA2 USP2 1951/4885SMN1; SMN2 2656/4885CTSK 3196/4885
US-20070232617-A1 INDOLE-TYPE DERIVATIVES AS INHIBITORS OF P38 KINASE MAPK1, MAPKAPK2, MAPKAPK5 USP2 2349/4885SMN1; SMN2 3749/4885CTSK 2900/4885
US-20260109716-A1 CEREBLON-BASED KRAS DEGRADING PROTACS AND USES RELATED THERETO KRAS, CRBN, HRAS USP2 255/4885SMN1; SMN2 3271/4885CTSK 738/4885
US-12637458-B2 Imidazo[1,2-a]pyridine compounds and their use in therapy OGFR, CBR3, CBR1 USP2 4064/4885SMN1; SMN2 2108/4885CTSK 2113/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.